Abstract
BACKGROUND: Injectable hyaluronic acid (HA) is the gold standard for the aesthetic treatment of facial volume and wrinkles. OBJECTIVES: The authors of this study aim to evaluate the safety and performance of 2 new HA fillers for the treatment of the lips and perioral area. METHODS: This multicenter prospective study enrolled 72 patients. All patients received lip enhancement with ESTYME LIPS (EST(LP), SYMATESE, Chaponost, France), and 61 of them also had correction for lip fine lines and nasolabial folds (NLFs) with ESTYME SMOOTH (EST(SM)). Assessments were conducted by injector-investigators, the patients, and an independent evaluator. The primary endpoint was the proportion of patients with at least 1 injection-site reaction (ISR) lasting beyond 14 days. Secondary endpoints included adverse events, aesthetic improvements, lip functionality, and participant satisfaction, assessed over 12 months. RESULTS: After 30 days, at least 1 ISR was observed in 35% of the participants on the lips, 2% on the fine lines, and 2% on the NLF. At 12 months, an improvement of at least 1 point was still observed in 66% of participants on the lips, 74% on the fine lines, and 54% on the NLFs. Throughout the study, lip functionality was not affected by their treatment and both assessors and patients rated overall aesthetic improvement and good satisfaction. CONCLUSIONS: In this limited cohort, EST(LP) and EST(SM) proved to be safe and effective options for lip enhancement as well as correction of NLFs and lip fine lines, demonstrating sustained results in the majority of patients for up to 12 months. LEVEL OF EVIDENCE: 4 (Therapeutic).